📰 Expansion Phase News
Page 2 - Expansion Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Expansion Phase. Real-time updates on events, politics, business and more.
September 15, 2022
DGAP-News: Aignostics GmbH / Schlagwort(e): Finanzierung Aignostics erhält 14 Millionen Euro „Series A“-Finanzierung für Weiterentwicklung KI-gestützter Pathologie 15.09.2022 / 09:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Aignostics erhält 14 Millio...
June 23, 2022
The natural gas industry has shown renewed affection for the natural gas-rich Haynesville Shale, but darker times may lie ahead unless proposed takeaway
March 1, 2022
/PRNewswire/ -- Ether Cards is now Galaxis, the self-serve web3 engagement platform where anyone can build and monetize dynamic utility-driven NFTs–without the...
March 1, 2022
/PRNewswire/ -- Ether Cards is now Galaxis, the self-serve web3 engagement platform where anyone can build and monetize dynamic utility-driven NFTs–without the...
March 1, 2022
/PRNewswire/ -- For more than half a century, Val Kilmer has been honing his art: be it literature, movies, poetry, painting, photography, or music. His...
January 25, 2022
Issued by the Japanese Patent Office A New Protection Covering Tedopi Until 2037 Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that
January 17, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
December 28, 2021
With the planned expansion of limited face-to-face classes next year, the Department of Education (DepEd) expressed optimism that more schools will be allowed to reopen their doors to their students. In a statement issued Tuesday, Dec. 28, DepEd said that Education Secretary Leonor Magtolis Brione
December 20, 2021
In Addition, Three Senior Executives Will Reinforce the Company’s Drug Development Engine ...
December 13, 2021
At the 2021 American Society of Hematology (ASH) Annual Meeting Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) presented the first preclinical data on